{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:06:57Z","timestamp":1787022417873,"version":"build-2736575974"},"reference-count":18,"publisher":"Japan Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1507\/endocrj.ej20-0371","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T18:05:48Z","timestamp":1601661948000},"page":"231-241","source":"Crossref","is-referenced-by-count":37,"title":["Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors"],"prefix":"10.1507","volume":"68","author":[{"given":"Hidefumi","family":"Inaba","sequence":"first","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ariyasu","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Iwakura","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Kurimoto","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Takeshima","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Morita","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Furuta","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneki","family":"Hotomi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Akamizu","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Inaba H, Ariyasu H, Takeshima K, Iwakura H, Akamizu T (2019) Comprehensive research on thyroid diseases associated with autoimmunity: autoimmune thyroid diseases, thyroid diseases during immune-checkpoint inhibitors therapy, and immunoglobulin-G4-associated thyroid diseases. Endocr J 66: 843\u2013852.","DOI":"10.1507\/endocrj.EJ19-0234"},{"key":"2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.24294\/ti.v2.i2.606","volume":"2","author":"H Inaba","year":"2018","unstructured":"2 Inaba H, Ariyasu H, Okuhira H, Yamamoto Y, Akamatsu H, et al. (2018) Endocrine dysfunctions during treatment of immune-checkpoint inhibitors. Trends in Immunotherapy 2: 1\u20139.","journal-title":"Trends in Immunotherapy","ISSN":"https:\/\/id.crossref.org\/issn\/2573-5985","issn-type":"print"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Arima H, Iwama S, Inaba H, Ariyasu H, Makita N, et al. (2019) Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocr J 66: 581\u2013586.","DOI":"10.1507\/endocrj.EJ19-0163"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Inaba H, Ariyasu H, Iwakura H, Ueda Y, Kurimoto C, et al. (2019) Comparative analysis of HLA between idiopathic and anti-PD-1 antibody induced isolated ACTH deficiency: a pilot study. Clin Endocrinol (Oxf) 91: 786\u2013792.","DOI":"10.1111\/cen.14082"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Kurimoto C, Inaba H, Ariyasu H, Iwakura H, Ueda Y, et al. (2020) Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci 111: 1468\u20131477.","DOI":"10.1111\/cas.14363"},{"key":"6","unstructured":"6 Ariyasu H, Inaba H, Ota T, Yamaoka H, Furukawa Y, et al. (2018) Thyrotoxicosis and adrenocortical hormone deficiency during immune-checkpoint inhibitor treatment for malignant melanoma. In Vivo 32: 345\u2013351."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Shiba M, Inaba H, Ariyasu H, , Kawai S, Inagaki Y, et al. (2018) Fulminant type 1 diabetes mellitus accompanied by positive conversion of anti-insulin antibody after the administration of anti-CTLA-4 antibody following the discontinuation of anti-PD-1 antibody. Intern Med 57: 2029\u20132034.","DOI":"10.2169\/internalmedicine.9518-17"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, et al. (2019) Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One 14: e0216954.","DOI":"10.1371\/journal.pone.0216954"},{"key":"9","unstructured":"9 Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T (1991) Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T (eds) HLA 1991: <i>Proceedings of the Eleventh International Histocompatibility Workshop and Conference. Vol. 1 Oxford University Press, Oxford, UK<\/i>, 1992; 1065\u20131220."},{"key":"10","unstructured":"10 Japanese Society for Histocompatibility and Immunogenetics: http:\/\/jshi.umin.ac.jp\/standarization\/JSHI-hyokiallele-2019list.pdf : JSHI accessed on March 1, 2020."},{"key":"11","unstructured":"11 HLA LABORATORY, Japan INC: http:\/\/hla.or.jp\/med\/frequency_search\/ja\/haplo\/ accessed on March 1, 2020."},{"key":"12","unstructured":"12 Ueda S, Oryoji D, Yamamoto K, Noh JY, Okamura K, et al. (2014) Identification of independent susceptible and protective HLA alleles in Japanese autoimmune thyroid disease and their epistasis. J Clin Endocrinol Metab 99: E379\u2013E383."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Taylor GM, Dearden S, Ravetto P, Ayres M, Watson P, et al. (2002) Genetic susceptibility to childhood common acute lymphoblastic leukemia is associated with polymorphic peptide-binding pocket profiles in HLA-DPB1*0201. Hum Mol Genet 11: 1585\u20131597.","DOI":"10.1093\/hmg\/11.14.1585"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Dai S, Murphy GA, Crawford F, Mack DG, Falta MT, et al. (2010) Crystal structure of HLA-DP2 and implications for chronic beryllium disease. Proc Natl Acad Sci U S A 107: 7425\u20137430.","DOI":"10.1073\/pnas.1001772107"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Inaba H, Martin W, Ardito M, De Groot AS, De Groot LJ (2010) The role of glutamic or aspartic acid in position four of the epitope binding motif and thyrotropin receptor-extracellular domain epitope selection in Graves\u2019 disease. J Clin Endocrinol Metab 95: 2909\u20132916.","DOI":"10.1210\/jc.2009-2393"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Inaba H, De Groot LJ, Akamizu T (2016) Thyrotropin receptor epitope and human leukocyte antigen in Graves\u2019 disease. Front Endocrinol (Lausanne) 7: 120.","DOI":"10.3389\/fendo.2016.00120"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17 Vita R, Guarneri F, Agah R, Benvenga S (2014) Autoimmune thyroid disease elicited by NY-ESO-1 vaccination. Thyroid 24: 390\u2013394.","DOI":"10.1089\/thy.2013.0170"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Kotwal A, Kottschade L, Ryder M (2020) PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid 30: 177\u2013184.","DOI":"10.1089\/thy.2019.0250"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/2\/68_EJ20-0371\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T22:30:15Z","timestamp":1614983415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/2\/68_EJ20-0371\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej20-0371","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}